title: Exenatide may improve maintenance of HbA1c targets, with less hypoglycaemia, but more early adverse effects when compared with low-dose glimepiride.
authors.affiliation: Department of Family Medicine, University of Alberta, , Edmonton, Alberta, Canada.
authors.forename: Denise L
authors.initials: DL
authors.lastname: Campbell-Scherer
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Johnson
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008297:Male; D010455:Peptides / Q000008:administration & dosage*; D013453:Sulfonylurea Compounds / Q000008:administration & dosage*; D014688:Venoms / Q000008:administration & dosage*
chemical_list: D007004:Hypoglycemic Agents; D010455:Peptides; D013453:Sulfonylurea Compounds; D014688:Venoms